Abstract. The persistent infection by human papilloma virus (HPV) is considered to be the major risk factor of cervical cancer, which is one of the most common cancers in women worldwide. Millions of women are currently infected with high-risk HPV. Thus, it is urgent to develop therapeutic vaccines to eliminate established infection or HPV-related diseases. In the present study, we constructed a very promising therapeutic HPV16 protein vaccine of optimized E7 (oE7)/huhsp70 using human huhsp70 linked to HPV16 oE7. Our results demonstrated that vaccination with the oE7/huhsp70 protein vaccine induced a very strong E7-specific CD8+ T cell immune response and resulted in a significant therapeutic effect against E7-expressing tumor cells. Our study verifies that huhsp70 is an effective immune adjuvant in the development of tumor therapeutic protein vaccines, and emphasizes that homologous huhsp70 is a promising tool in future human clinical applications.

Introduction

Cervical cancer is a malignant neoplasm arising from cells originating in the cervix uteri. The development of cervical cancer are closely associated with constitutive infection of HPV viruses, of which HPV16 is the most common high-risk type, accounting for more than half (56%) of all cervical cancers (1). It is well known that Harald zur Hausen, the German researcher who discovered the human papilloma-virus, was awarded Noble Prize in Medicine on 2008. The finding of HPV makes prevention and treatment of cervical cancer possible. In addition to preventive vaccines, such as Gardasil and Cervarix (2,3), laboratory researches are paying attention to the treatment of cervical cancer that has been developed. Preventive vaccines do not cause therapeutic effects on existing lesions, thus, it is urgent to focus on the treatment of pre-existing lesions. In addition to traditional surgery, chemotherapy and radiotherapy, therapeutic HPV vaccines are attracting our attention. HPV E7 oncoprotein represent an ideal target for therapeutic intervention because of its constitutive expression in HPV-associated tumors (4,5).

Versatile therapeutic strategies have been developed (6-10). Various therapeutic HPV vaccines are aiming to interact with professional antigen-presenting cell (APC) such as dendritic cell (DC) to generate specific cell-mediated immunity for clearance of infection and control of HPV-associated cancers (11,12). Protein-based therapeutic HPV vaccines are vaccine candidates commonly tested in clinical trials, compared to other forms of therapeutic HPV vaccines (13). Protein vaccines have some advantages in vaccine development. For example, compared to live-vector based vaccines they are safe. Protein vaccines contain all possible peptide epitopes interacting with the MHC I and II epitopes, so they are not limited by the specificity of MHC. However, protein vaccines are troubled by their low immunogenicity. To overcome this problem and to enhance their potency, we design two novel new strategies, one is optimization of E7 protein by adding MHC-I epitope at C terminal and MHC-II epitope at N terminal of fusion protein, and another is the addition of human hsp70 (huhsp70) adjuvant.

Effective antigen process and presentation is the indispensable condition to induce a strong and specific CD8+ T cell response. Because the normal capacity of APC to cross-present antigen is generally low, there is significant interest to develop strategies that enhance the targeting of exogenous antigens to the cross-presentation pathway (14,15). Critical factors that
determine the efficacy of a vaccine are the amount of delivered antigen and the surroundings in which the antigen is presented to the T cells. The addition of MHC I epitope at C terminal and MHC II epitope at N terminal of fusion protein, makes more specific antigen peptides to act with MHC molecules, so that it enlarges the rate of recognition for MHC molecules. Thus, the delivery of more antigens to the MHC class I cross-presentation pathway is one of the keys to the improved capacity of APCs to activate antigen-specific T cells.

Another strategy is the use of hsp70 to enhance the antigen cross presentation. As an intracellular protein, hsp70 has been shown to play multiple roles in protein folding, transport, and degradation act as molecular chaperones (16). However, it is reported that hsps also are involved in the immune activation in that they transfer their chaperoned protein-cargo to APC for cross-presentation as an extracellular protein released when necrotic cells or secretion in response to cellular stress. Such antigenic cross-presentation is now considered to be a very important process in the action of hsp70 (17-20). The extracellular hsp70 is considered to mediate stimulation of DCs to secrete proinflammatory cytokines and express costimulatory molecules, thus creating the immunogenic environment required for the induction of adaptive CD8+ T cell responses. Several endocytic receptors, such as CD91 and LOX1 have been identified to take part in hsp70-mediated cross-presentation (21,22). When hsp70 binds to its corresponding receptors of CD40, TLR-2 and TLR-4 on the DC, enters the cell plasma and induces activation and maturation DC (23-25). Hsp70 not only activates and regulates innate immunity but also the adaptive immunity. The above attributes of hsp70 suggest its rational use in immunotherapeutic strategies for the treatment of cancer. Thus, this activity of hsp70 is desirable for therapeutic vaccine development.

Our previous study on HPV16 E7/hsp70 DNA vaccine has shown that huhsp70 enhanced more effective antitumor efficacy than mycobacterium tuberculosis hsp70 (26). In this protein vaccine study, we optimized the E7 protein by site-directed mutagenesis to eradiate the transformation activity, MHC epitope and human hsp70 adjuvant were added to strengthen the cross-presentation potential, and developed the fusion protein of oE7/huhsp70, expecting to produce enhanced antitumor efficacy.

Materials and methods

Mice and tumor cell line. Female C57BL/6 mice of 6-8-week-old were maintained in the Animal Facility of the Laboratory Animal Center, the Affiliated Hospital of Medical College of Qingdao University. All animal procedures were performed according to the approved protocols and in accordance with recommendations for the proper use and care of laboratory animals. Care was taken to minimize pain and discomfort to all animals during the procedures in this study. TC-1 cells purchased from Shanghai Meilian Biotechnology Co., Ltd., (Shanghai, China) were primary pulmonary epithelial cells of C57BL/6 mice co-transformed with HPV16 E6, E7 and activated c-Ha-ras oncogenes. The cells were grown in RPMI-1640 supplemented with 10% (v/v) fetal bovine serum, 50 U/ml penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 2 mM non-essential amino acids and 0.4 mg/ml G418 at 37°C with 5% CO2.

Plasmids construction. HPV16 oE7 gene was synthesized by Shanghai Generany Biotech Co., Ltd. (Shanghai, China) and cloned into pMD18T vector by using two primers, forward primer 5'-GCCATATGATGACAGCTCAGAGGAGG-3' (Ndel) and reverse primer 5'-CCGGATCCGGTTACAATATGGA-3' (BamHI), then was subcloned into pET-30a (+) (Novagen, Darmstadt, Germany) and generated the pET-30a (+)-oE7. The huhsp70 gene (GenBank NM_005345) was amplified by using forward primer 5'-GGGATCCGGTTACAATATGGA-3' (BamHI) and reverse primer 5'-CGCTCGAGCTATACCTCCTCAATTTG-3' (Xhol) from pM5SHsp70, a gift of Prof. R.I. Morimoto of the Northwestern University (Evanston, IL, USA), then subcloned into pET-30a (+) and generate pET-30a (+)-huhsp70. To generate pET-30a (+)-oE7/huhsp70, huHSP70 digested with BamHI and Xhol from pET-30a (+)-huhsp70 was ligated into BamHI/Xhol-digested pET-30a (+)-oE7 without the stop code of oE7. All constructs were validated by restriction enzyme digestion and DNA sequencing.

Expression, purification and analysis of oE7, huhsp70 and oE7/huhsp70 proteins. E. coli strain BL21 (DE3) (Novagen) was used as the host bacterial for all recombinant protein production. All transformants were grown in Luria Broth (LB) medium containing 50 µg/ml kanamycin. When OD600 reach about 0.5, engineered bacterial was induced with 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) for 4 h at 37°C. Cells were harvested by centrifugation at 10,000 x g for 10 min at 4°C, the supernatant was discarded and the cells resuspended in 4 ml cold binding buffer with 0.1% NP-40. Using the His•Bind® Purification kit (Novagen, No. 70239) to purify these recombinant proteins. The identity and the purity of the recombinant proteins were determined by SDS-PAGE. Concentrations of proteins were measured by the Bradford assay. To confirm the identity of the recombinant protein, all purified recombinant proteins were verified by western blot analysis against the human hsp70 antibody (sc-32239; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and/or HPV16 E7 antibody (sc-51951; Santa Cruz Biotechnology).

ELISPOT assay. BD ELISPOT plates (BD BioSciences) were coated with 5 µg/ml rat anti-mouse IFN-γ antibody in 100 µl of PBS. After overnight incubation at 4°C, the wells were washed and blocked with RPMI-1640 culture medium containing 10% fetal bovine serum. Different concentrations of freshly isolated spleen cells from each vaccinated mouse group, from 1×106 to 1.25×107/well, were added to the wells along with 50 IU/ml IL-2 and 1 µg/ml E7-specific MHC class I CD8+ T cell epitope (H-2 Db, amino acids 49-57, RAYHYNIVTF). After culture at 37°C for 24 h, the plate was washed and then followed by incubation with 2.5 µg/ml biotinylated IFN-γ antibodies in 100 µl in PBS containing 10% FCS at 4°C overnight. After washing, avidin-HRP in 100 µl of PBS was added and incubated for 1 h at room temperature. After washing five times, spots were developed by addition of 100 µl AEC solution. The spots were counted using an ELISPOT Reader system.
Flow cytometry analysis to detect IFN-γ secretion by E7-specific CD8+ T cells. To detect E7-specific CD8+ T-cell responses, splenocytes from vaccinated groups of mice were incubated with the MHC class I E7 peptide. Golgistop (BD Biosciences) was added 6 h before harvesting the cells from the culture. The cells were then washed once in staining buffer and labeled with FITC-conjugated rat anti-mouse CD8 antibodies. The cells were fixed and permeabilized using a Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s instructions and then were stained for PE-conjugated anti-IFN-γ, FITC-conjugated rat IgG2a, or PE-conjugated rat IgG1 isotype control antibody were all purchased from BD BioSciences. Analyses were performed on a Beckman Coulter Epics XL (Beckman Coulter Inc., Brea, CA, USA).

Cytotoxicity assays. C57BL/6 mice were immunized intramuscularly (i.m.) with PBS, 2 nmol oE7, huhsp70 and oE7/hsp70 at the M. quadriceps, respectively. These injections were repeated after 1 week. Two weeks after the last booster, 1x10⁶ splenocytes were cocultured with 5x10⁴ irradiated TC-1 helper cells in RPMI-1640 supplemented with 10% FCS and 20 U/ml IL-2 at 37˚C in 5% CO₂. After 3 days of stimulation, TC-1 target cells were plated at 1x10⁵ cells/well on 96-well U-bottomed plates (Costar), then the prepared splenocytes (effector cells) were added in a final volume of 100 µl at 40:1, 20:1, 10:1 and 5:1 ratio, respectively. The CytoTox 96 NonRadioactive Cytotoxicity Assay kit (Promega Inc.) was used to determine the cytotoxic activity of the effector cells against TC-1 tumor cells according to the manufacturer’s protocol. The percentage of cytotoxicity was calculated by the formula: [(A (Experimental) - A (Effector spontaneous) - A (Target spontaneous)] x 100/(A (Target maximum - Target spontaneous)].

Anti-E7 ELISA. The anti-HPV16 E7 antibodies in the sera of vaccinated mice were identified by ELISA. Each well of a 96-microwell plate was coated with 100 µl of 1 µg/ml purified HPV16 oE7 proteins and incubated at 4˚C overnight. The wells were then blocked with PBS containing 5% BSA. Two weeks after the last booster, sera were prepared from the mice, serially diluted in PBS, added to the ELISA wells and incubated for 2 h. After washing with PBS-T containing 0.05% Tween-20, the plate was incubated with 1:3,000 dilution of an HRP-conjugated goat anti-mouse IgG antibody (sc-2005; Santa Cruz Biotechnology) at room temperature for 1 h. The plate was washed three times, tetramethyl-benzidine substrate was added and incubated away from light at 37˚C for 15 min. The reaction was stopped with 50 µl of 2 M H₂SO₄. The ELISA plate was read with a standard ELISA reader at 450 nm.

In vivo tumor treatment experiments. To test the ability of protein vaccination to inhibit the growth of established tumors, C57BL/6 mice (five/group) were subcutaneously (s.c.) challenged with 7.5x10⁴ TC-1 cells per mouse in the right flank. Three days after the challenge with TC-1 cells, mice were given 200 µl of PBS, 2 nmol oE7, huhsp70 or oE7/huhsp70. One week later, these mice were strengthened with the same regimen as the first vaccination. Mice were monitored twice a week for tumor growth.

Statistical analysis. The mean of two sample comparison of Poisson distribution was used to analyze ELISPOT and FACS data. ELISA with the Student’s t-test, cytotoxicity assays and tumor treatment data were analyzed by the Fisher’s exact probabilities in a 2x2 table. Differences were considered statistically significant at P<0.01.

Results

Production and analysis of recombinant proteins. oE7, huhsp70 and oE7/huhsp70 recombinant proteins were expressed effectively in E. coli BL21 in a form of inclusion body. All proteins with his-tag were purified by the His®Bind® Purification kit. All recombinant proteins were purified to >90%. The recombinant proteins used in this study contained <0.05 endotoxin units (EU)/µg as measured by the chromogenic Limulus amebocyte lysate assay. Concentrations of proteins were measured by the Bradford assay. The expression and analysis of recombinant proteins were confirmed by western blot analysis (Fig. 1).

oE7/huhsp70 fusion protein significantly induces strong E7-specific CD8+ T cell responses. CD8+ T cells are the most important cells involved in antitumor effect, while the ELISPOT assays and flow cytometry analysis are the two representative methods. To evaluate whether oE7/huhsp70 is able to prime strong E7-specific CD8+ T cells, oE7 or huhsp70, the mice were immunized i.m. with 200 µl of PBS, 2 nmol oE7, huhsp70 or oE7/huhsp70, which was repeated after 1 week. Two weeks after the second immunization, splenocytes were harvested and stimulated with 1 µg/ml H-2Db-restricted E7 peptide. In ELISPOT assays, as shown in Fig. 2, vaccination with oE7/huhsp70 generated significantly higher percentage of E7-specific IFN-γ-secreting CD8+ T cell precursors than PBS, oE7 or huhsp70. Similar results were also obtained by intracellular IFN-γ staining with flow cytometry analysis. As shown in Fig. 3, vaccination with oE7/huhsp70 also generated the highest percentage of E7-specific IFN-γ-secreting CD8+ T cell precursors compared to the others. In accordance with the ELISPOT and flow cytometry analysis, cytotoxicity assays showed that splenocytes of the mice immunized with oE7/
huhsp70 were more cytotoxic to TC-1 target cells expressing E7 than those in the mice immunized with PBS, oE7 or huhsp70 (P<0.01) (Fig. 4). Taken together, our results suggest that oE7/huhsp70 fusion protein vaccine generates the highest E7-specific CD8$^+$ T cell response compared with the other vaccinated groups. Results shown here are from one representative experiment of three repeated experiments.

Vaccination with oE7/huhsp70 induces an E7-specific antibody response. The quantity of anti-HPV16 E7 antibodies in the sera of the vaccinated mice was determined by ELISA 2 weeks after the last vaccination. As shown in Fig. 5, only mice vaccinated with oE7/huhsp70 fusion protein produce a robust antibody response (P<0.01), indicating that secreted oE7/huhsp70 stimulates B-cell responses.

Tumor treatment experiments. In order to examine the E7-specific CD8$^+$ T response elicited by oE7/huhsp70 fusion protein further, we investigated the efficacy of each vaccine to induce the eradication of pre-existing TC-1 tumor expressing E7 in vivo. Female C57BL/6 mice were challenged with 7.5x10$^4$ TC-1 cells per mouse s.c. in the right flank. Three days after the challenge with TC-1 cells, mice were given 200 µl of PBS, 2 nmol oE7, huhsp70 or oE7/huhsp70. One week later, these mice were boosted with the same procedure as the first vaccination. As shown in Fig. 6, 100% of the mice immunized with oE7/huhsp70 were tumor-
free until day 45. In contrast, mice receiving PBS or huhsp70
developed tumor growth on the 12th day until the 45th day,
while 4 mice receiving oE7 developed tumor growth on the
12th day and 1 mouse developed tumor growth on the 16th
day until the 45th day. There was a statistically significant
difference in the therapeutic effect of TC-1 tumor between
oE7/huhsp70 and other vaccinated group (P<0.01). These
results show that oE7/huhsp70 fusion protein vaccine is
the most potent and promising therapeutic vaccine against
E7-expressing tumors among the various protein vaccines
which we have tested.

Discussion

Results of the present study revealed that fusion protein of
oE7/huhsp70 not only stimulated very strong CD8+ T-cell responses but also induced an effective E7 antibody response, indicating that E7-specific CD8+ T-cell responses and B cell mediated humoral immunity play important roles in anti-tumor effect with this protein vaccine, T helper cell responses might be simultaneously produced. The previously reported increased HPV-16 E7-specific IgG levels appeared to be correlated with a positive therapeutic effect (27). An important condition of tumor adaptive immunity is MHC I and II presentation of self and nonself peptides to CD8+ T and CD4+ T cells respectively. Endogenous antigens are generally presented by MHC I, and exogenous antigens by MHC II. In the present study, the addition of MHC-I epitope at C terminal and MHC-II epitope at N terminal of fusion protein, aimed to enhance the quantity of epitope, increased the chance of involvement of antigen presentation, and strengthened the E7-specific CD8+ T-cell responses and E7 antibody response.

It is well known that exogenous antigens can also be inter-
nalized and displayed by MHC I molecules through a widely
accepted mechanism, called as cross-priming or cross-presen-
tation. Many studies have recognized and confirmed that hsp70
is involved in the antigen cross-priming and induction of effec-
tive tumor specific CD8+ T-cell responses (19,20,28). It has been
shown that pathogen-derived molecules are danger signals and
are able to activate innate immunity that in turn regulates and
influences development of adaptive immunity (29,30). For
example, mycobacterium tuberculosis heat shock protein 70
has been shown to exert a potent adjuvant effect in therapeutic
vaccination against tumors (31). These studies suggest that
mycobacterium tuberculosis also act as danger signal aside
from the molecular chaperon and cross-presentation function.
However, it is clear that there is no shortage of controversy on
the action mechanism of the different species originated hsp70
in tumor therapeutic vaccines. Bendz et al (15) have shown
that huhsp70 enhances tumor antigen presentation through
complex formation and intracellular antigen delivery without
innate immune signaling; in addition, the fusion DNA vaccine of
mouse hsp70 with HPV16 E7 showed that autologous hsp70
was highly potent in enhancing antigen-specific immune
responses (32). These previous therapeutic HPV vaccine
reports showed that whether mouse or human hsp70, especially
huhsp70 induced very strong effective CD8+ T-cell responses
and antitumor effect, even 100% of mice were tumor-free until
day 60 after in vivo TC-1 challenge in tumor protection and
treatment experiments (26), which indicated that hsp70 plays
an important role in tumor therapeutic vaccine not for its
danger signal alerting ability but for its molecular chaperon
and cross-presentation function. Thus, huhsp70 fulfills these
central requirements of a tumor vaccination tool and a strong
immune adjuvant.

Safety also is a critical factor to be considered during
development of effective vaccines. The safety problem of
oE7/huhsp70 fusion protein vaccine originates from two areas,
one is the potentially malignant transformation activity of E7
protein, and another is the homology of hsp70 adjuvant itself.
E7 protein has a tendency to bind with the tumor suppressor
protein pRB of the host, resulting in chromosomal aberration
and finally development of malignant transformation of
the host cells. In order to eradicate the transformation
activity of E7 and enhance its immunogenicity, we muted
two zinc finger binding areas and the pRB binding area of
E7. Hsp70 are highly conserved from prokaryotic to eukary-
otic organisms not only functionally but also structurally.
However, allogenous hsp might induce immune reaction to
interrupt the recognition of antigen and antigen presenting
cells in mouse or human (33), or trigger the induction and
expansion of regulatory T-cells with immunosuppressive
functions (34,35). A potential safety concern arises from the
existence of T-lymphocytes cross-reactive with mycobacte-
rial and human hsp (36). Although we cannot discount this
risk entirely, we believe that in a clinical setting the use of a
human protein will reduce the risk of autoimmunity due to
cross-reactive T-lymphocytes primed by the hsp70 vaccines.
Mycobacterium tuberculosis, mouse and human hsp70 can
induce effective antitumor effects, being a self-protein,
toxicity issues are unlikely to occur, taking into account the
future clinical test safety, we recommend self huhsp70 as a

Figure 6. In vivo tumor treatment experiments. Vaccination with oE7/huhsp70
protein enhanced the antitumor immunity more significantly than PBS,
oE7 and huhsp70. Vaccination with oE7/huhsp70 protein eradicated pre-
implanting TC-1 tumor cells, 100% of mice were tumor-free until day 45
after TC-1 challenge, while 100% of mice vaccinated with PBS, huhsp70
form a tumor at the 12th day and maintain the tumor until day 45 except
the mice vaccinated with oE7 forming a tumor at day 16. Each mouse was
initially challenged s.c. with 7.5x10^4 TC-1 cells in the right flank and then was
vaccinated i.m. with PBS, oE7, huhsp70 and oE7/huhsp70 on days 3 and 10.
The mice were monitored for tumor growth twice a week, each group com-
pri ed five mice. The results shown here are from a representative experiment
of two performed.

MHC II. In the present study, the addition of MHC-I epitope
at C terminal and MHC-II epitope at N terminal of fusion
protein, aimed to enhance the quantity of epitope, increased
the chance of involvement of antigen presentation, and
strengthened the E7-specific CD8+ T-cell responses and E7
antibody response.
potential and promising candidate adjuvant to help the therapeutic vaccine to produce enhanced antitumor effects.

In summary, huhsps70 may be a useful and promising antigen delivery vehicle for a wide variety of antigens, cross-presentation is applicable for APC and in various settings of immune modulation. Our findings not only provide novel insights into the mechanism by which huhsps70 stimulates T cell responses but also provide reference for the development of highly effective molecular tools and immune adjuvant in other tumor biological treatments.

Acknowledgements

We gratefully acknowledge Professor Richard I. Morimoto (Northwest University, Evanston, IL, USA) for kindly providing the pMSHsp70 plasmid and Professor Xuemei Xu (Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China) for providing the PVR1012mE7/HuHS70 plasmid. The present study was supported by a grant from the Nature Science Foundation for Young Scholars of Shandong Province (ZR2010HQ009).

References
